Infectious Diseases and Vaccines Agenda

Programme:

08.30 - Registration opens

09.30 - Welcome, Harriet Fear, One Nucleus

09.45 - Opening Plenary Session

09.45 - Partnering Models to Address Global Health Challenges

Tim Wells, CSO, Medicines for Malaria Venture

10.15 - Infectious Diseases Across the Ages – the Seven Ages of Man
David McIntosh, Global Scientific Affairs Senior Expert, Novartis Vaccines & Diagnostics

10.45 - Morning Refreshments

11.15 - Developing the Anti-Infective Pipeline

11.15 - Introduction from the Chair
Keith Powell, Domainex

11.25 - Bacteria, Fungi and Viruses: The Therapeutic Challenges
David Knowles, Procarta Biosystems

11.45 - Non-cyclosporin Cyclophilin Inhibitors to Treat Hepatitis C Infection
Barrie Wilkinson, Vice President R&D Biotica Ltd

12.00 - SASPject™ - A New Concept in Anti-Bacterial Drug Development
Heather Fairhead, CEO, Phico Therapeutics

12.15 - Addressing the Anti-Fungal Challenge
Deborah O’Neil, CEO, NovaBiotics

12.30 - Next Generation Antibiotics: One Bug, One Drug
David Williams, CEO, Discuva Limited

12.45 - Lunch

13.45 - Prevention Better than Cure?

13.45 - Introduction from the Chair
Richard Broadhead, Technical Sales Manager, Oxford Expression Technologies 

13.55 - Is Forewarned Really Forearmed: Preparedness Through Infectious Disease Surveillance?
Miles Carroll, Deputy Director, Head of Research, Health Protection Agency

14.10 - Dendritic Cell Stimulation to Enhance Efficacy
Graham Clarke, CEO, ImmBio

14.25 - Utilising Live Bacterial Vectors for Oral Delivery of Vaccines
Ted Fjallman, Technology Development Coordinator, Prokarium Ltd

14.40 - DepoVaccine: Next Generation Peptide Vaccine Technology
Campbell Bunce, R&D Director, Immune Targeting Systems   

14.55 - Prophylactic and Therapeutic Approaches to S Aureus
Fiona Marston, CEO, Absynth Biologics  

15.10 - Utilising Tandem Core Constructs to Enhance Immune Response
Mike Whelan, Head of R&D, iQur Therapeutics 

15.25 - Afternoon Refreshments

16.00 - More With Less: Innovation in R&D Technology and Strategy for Better Medicines Faster

16.00 - Introduction from the Chair
Gerard Gregg-Smith, Managing Director, GGS-Associates, Clinova Ltd

16.10 - A Broadly Applicable Vaccine Stablisation Technology
Jeff Drew, CSO, Stabilitech

16.25 - Validating Pre-Clinical Infection Models
Neil Williams, CSO, KWS BioTest

16.40 - Improved Formulations to Address Stability of Innovative Products
Tom Saylor, CEO, Arecor

16.55 - Amphotericin B: Using Polymeric Complexes to Increase Solubility
Steve Brocchini, CSO, Polytherics

17.10  - Closing Plenary Speaker
Targeting Dormant Bacteria as a New Approach to Identifying Innovative New Targets and Drugs
Professor Sir Anthony Coates, St George’s, University of London and Helperby Therapeutics

17.35 - Drinks Reception

19.00 Close